Investor FAQs


 

Idenix Pharmaceuticals is incorporated in Delaware.

Idenix headquarters is located at 320 Bent St., 4th Floor, Cambridge, MA 02141.

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 Phone: (617) 526-6000 Fax: (617) 526-5000

PricewaterhouseCoopers, LLP One International Place Boston, MA 02110 United States of America Telephone: (617) 530 5000 Telecopier: (617) 530 5001

Our fiscal year-end is December 31st. Reporting quarters correspond with calendar quarters.

Idenix's common stock began trading on July 22, 2004. The pricing of its initial public offering of 5.8 million shares of common stock was $14.00 per share. Idenix offered 4.6 million shares and certain selling stockholders of Idenix offered 1.2 million shares. Concurrent with the initial public offering, Idenix also agreed to a private placement of 5.4 million shares to Novartis at the initial public offering price to be completed concurrently with the consummation of the initial public offering.

Idenix Pharmaceuticals is listed on the Nasdaq Global Market under the ticker symbol IDIX.

You can purchase Idenix stock through any registered broker. Idenix does not have a Direct Stock Purchase Plan at this time.

The CUSIP# for the Idenix Common Stock is 45166R 20 4.

The transfer agent for Idenix Pharmaceuticals is Computershare Trust Company. For shareholder inquiries, please contact Shareholder Relations at the following address:

Computershare Trust Company, N.A. 250 Royall St. Canton, MA 02021 781-575-3400

Contact Computershare Trust Company, N.A. who can look up your records and make any necessary adjustments. There may be a fee involved for replacing lost stock certificates.

Please sign up for our E-mail Alerts for the most current investor and company news from Idenix or e-mail us your contact information at investor@idenix.com.

Please submit your question using the form below.

* Indicates required field